Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Evotec SE has inked a deal with Janssen Pharmaceutical hat showcases its end-to-end integrated drug discovery and development platform.
BioSpace looks at several companies developing new gene therapies in the wake of the FDA recommending two of bluebird bio’s lentiviral vector gene therapies.
Horizon Therapeutics’ Bill Rees spoke to BioSpace about the scientific discovery and collaboration potential of its new Rockville, Maryland site, which is expected to open in 2024.
AbbVie announced Friday that its investigational drug navitoclax, when used together with ruxolitinib, eases symptoms in myelofibrosis patients who had not yet been treated with a JAK inhibitor.
Owkin and BMS signed a deal to utilize Owkin’s artificial intelligence capabilities to carry out more targeted and efficient clinical trials on a wide range of therapeutic candidates.
Shape Therapeutics is evolving programmable RNA medicines that push the limits of current gene editing capabilities. BioSpace spoke with CSO David Huss.
Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.
Tessa Therapeutics, Synklino, Anagenex and Charm Therapeutics raise tens of millions of dollars in Series A financing.
The Forbion Growth Opportunities Fund II will invest mainly in later-stage biopharmaceutical firms in Europe, focusing on marketing treatments for diseases with high unmet needs.
Degron Therapeutics, based in Shanghai, announced Thursday that it has secured $22 million in Series A financing for its unique molecular glue-based targeted protein degradation platform GlueXplorer.